Prospective observational study to predict sensitive marker after administration of nintedanib in patients with idiopathic pulmonary fibrosis

Prospective observational study to predict sensitive marker after administration of nintedanib in patients with idiopathic pulmonary fibrosis - Exploratory investigation in idiopathic pulmonary fibrosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000022232

Enrollment

Registered

2016-05-09

Start date

2016-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary fibrosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically or radiologically diagnozed idiopathic pulmonary fibrosis PS of 0-2 Adequate organ function expected more than 3-month survivors Candidate for administration of nivolumab

Exclusion criteria

Exclusion criteria: Judgement as exclusion by chief mdical physians Acute crdac infarcton or angina pectoris Candidate for lung transplntation With malignant disease

Design outcomes

Primary

Measure	Time frame
To explore the pretictive biomarkers after and before Nintedanib using blood samples.	—

Countries

Japan

Contacts

Public ContactKyoichi Kaira

Gunma University Graduate of Medicine Department of Oncology Clinical Development

kkaira1970@yhoo.co.jp027-220-8122

Outcome results